HemostOD is a Swiss biotech company that specializes in the engineering and manufacturing of universal platelets, leveraging advanced technologies to address critical medical needs. Their lead program focuses on thrombocytopenia, aiming to develop universal platelets for patients who are at risk of HLA immune-refractoriness. Additionally, HemostOD employs its proprietary CAR-PLT® technology for targeted delivery of therapeutic agents, such as miRNA/siRNA or proteins, to specific tissues. The company also explores regenerative medicine applications, utilizing engineered platelets for wound healing and immunomodulation, as well as enhancing the culture of therapeutic stem cells through platelet lysate derived from their universal platelets.

The innovative manufacturing platform developed by HemostOD is inspired by the natural generation of platelets in the bone marrow. This platform integrates molecular and cell biology techniques to create a stable megakaryocytic cell line, followed by advanced microfluidic technologies to efficiently produce high-quality platelets. The process is designed to be robust, scalable, and rapid, allowing for the generation of large quantities of homogeneous platelets within hours. HemostOD's intellectual property includes methods for immortalizing hematopoietic progenitor cells, engineering cells for specific features, and ex-vivo generation of platelets, positioning the company at the forefront of platelet technology and its diverse applications in medicine.

Switzerland

HemostOD is a biotech company based at the EPFL Innovation Park in Lausanne, Switzerland. They are a preclinical stage company developing a therapeutic platform inspired by platelet biology.

HemostOD

Company Details